Table 2

LVEF, LVEDV, and VO2max Before CRT and at 12-Month Follow-Up for Patients With Viable or Nonviable LV Lead Segment

LV Lead Position Determined During Pure LV Pacing
LVEF, %
 Viable segment of LV lead position
  Baseline LVEF31 ± 5
  Follow-up LVEF42 ± 6
  ΔLVEF11 ± 4
 Nonviable segment of LV lead position
  Baseline LVEF30 ± 7
  Follow-up LVEF35 ± 6
  ΔLVEF5 ± 4
 Difference in ΔLVEF
  (viable – nonviable group)6.0
  (95% CI)(2.5–7.9)
 p value for ΔLVEF (viable vs. nonviable group)0.0343
LVEDV, ml
 Viable segment of LV lead position
  Baseline LVEDV321 ± 54
  Follow-up LVEDV263 ± 62
  ΔLVEDV58 ± 13
 Nonviable segment of LV lead position
  Baseline LVEDV316 ± 59
  Follow-up LVEDV272 ± 60
  ΔLVEDV44 ± 12
 Difference in ΔLVEDV
  (viable – nonviable group)14.0
  (95% CI)(8.6–16.3)
 p value for ΔLVEDV (viable vs. nonviable group)0.0388
VO2max, ml/kg/min
 Viable segment of LV lead position
  Baseline VO2max13.4 ± 1.3
  Follow-up VO2max15.9 ± 1.6
  Δ VO2max2.5 ± 0.8
 Nonviable segment of LV lead position
  Baseline VO2max13.4 ± 1.3
  Follow-up VO2max15.1 ± 1.5
  Δ VO2max1.7 ± 1.1
 Difference in Δ VO2max, ml/kg/min
  (viable – nonviable group)1.0
  (95% CI)(0.4–1.8)
 p value for ΔVO2max (viable vs. nonviable group)0.0465

The LV lead position was defined with myocardial deformation imaging during pure LV pacing.

CI = confidence interval; other abbreviations as in Table 1.